钠-葡萄糖共转运蛋白-2抑制剂的药理学与临床评价  

Pharmacology of and Clinical Evaluation on Sodium Glucose Co Transporter 2 Inhibitors

作　　者：王建民[1] 付燕霞[1] 

机构地区：[1]北京军区总医院,北京100730

出　　处：《中国医院用药评价与分析》2014年第10期887-889,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨钠-葡萄糖共转运蛋白-2(SGLT-2)抑制剂的药理学作用与临床应用。方法:采用文献分析方法,对国内外SGLT-2抑制剂相关文献进行检索,评价SGLT-2抑制剂的临床疗效与安全性。结果与结论:SGLT-2抑制剂为一类新型抗糖尿病药,临床上用于饮食和运动控制治疗后效果不佳的2型糖尿病者。SGLT-2抑制剂的作用机制与口服降糖药截然不同,其非在于促进胰岛β细胞分泌胰岛素,作用不依赖胰岛素,可延缓糖尿病的进程,发生低血糖的风险小,具有良好的应用前景,但其安全性、经济性、临床获益有待更长期的临床研究来证明。OBJECTIVE： To explore the pharmacology of and clinical evaluation about sodium glucose co transporter 2 （SGLT-2） Inhibitors. METHODS： By reviewing pertinent literature both at home and abroad about the related articles of sodium-glucose cotransporter-2 to evaluate the pharmacology of and clinical evaluation. RESULTS ＆ CONCLUSIONS： Sodium-glucose cotransporter-2 inhibitor is completely different form oral hypoglycemic agent in the mechanism of action in that its action doesn＇ t rely on the promotion of pancreatic β-cell to secrete insulin nor dependent on insulin, however, it can delay the progression of diabetes and lower the risk of hypoglycaemia, which thus has a good application prospect, but it＇ s safety ,economy and the clinical benefit need more long-term clinical studies to prove.

关 键 词：坎格列净 2型糖尿病 钠-葡萄糖共转运蛋白-2抑制剂 临床评价 

分 类 号：R977.15[医药卫生—药品]